{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=50", "query": { "intervention": "Level B", "page": 50 }, "page_size": 10 }, "pagination": { "page": 50, "page_size": 10, "total_count": 1436, "total_pages": 144, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=51&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Level+B&page=49&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-28T13:39:31.223Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01186328", "title": "EZN-3042 Administered With Re-induction Chemotherapy in Children With Relapsed Acute Lymphoblastic Leukemia (ALL)", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Lymphoblastic Leukemia, Acute", "Lymphoblastic Leukemia, Acute, Childhood", "Leukemia, Lymphoblastic, Acute, T Cell", "Leukemia, Lymphoblastic, Acute" ], "interventions": [ { "name": "EZN-3042", "type": "DRUG" }, { "name": "Cytarabine", "type": "DRUG" }, { "name": "Doxorubicin", "type": "DRUG" }, { "name": "Prednisone", "type": "DRUG" }, { "name": "Vincristine", "type": "DRUG" }, { "name": "PEG-asparaginase", "type": "DRUG" }, { "name": "Methotrexate", "type": "DRUG" }, { "name": "Hydrocortisone", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Therapeutic Advances in Childhood Leukemia Consortium", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "1 Year", "maximum_age": "21 Years", "sex": "ALL", "summary": "1 Year to 21 Years" }, "enrollment_count": 6, "start_date": "2010-08-24", "completion_date": "2012-01-10", "has_results": true, "last_update_posted_date": "2024-02-01", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 6, "location_summary": "Los Angeles, California • Baltimore, Maryland • Minneapolis, Minnesota + 2 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "Minneapolis", "state": "Minnesota" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT01186328" }, { "nct_id": "NCT01928472", "title": "Dose-finding Study of Four Dosage Levels of an H7N9 Influenza Vaccine in Adults Between Ages of 18 Years and 65 Years", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "H7N9 Influenza" ], "interventions": [ { "name": "H7N9c low dose with adjuvant", "type": "BIOLOGICAL" }, { "name": "H7N9c medium dose with adjuvant", "type": "BIOLOGICAL" }, { "name": "H7N9c high dose with adjuvant", "type": "BIOLOGICAL" }, { "name": "H7N9c high dose without adjuvant", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Novartis Vaccines", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 402, "start_date": "2013-08", "completion_date": "2014-09", "has_results": true, "last_update_posted_date": "2019-06-11", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 6, "location_summary": "San Diego, California • Melbourne, Florida • Peoria, Illinois + 2 more", "locations": [ { "city": "San Diego", "state": "California" }, { "city": "Melbourne", "state": "Florida" }, { "city": "Peoria", "state": "Illinois" }, { "city": "Rockville", "state": "Maryland" }, { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT01928472" }, { "nct_id": "NCT07190300", "title": "TulmiSTAR-02: A Phase I/II Open-label Study of Tulmimetostat in Combination With Darolutamide vs. Darolutamide, and Tulmimetostat With Abiraterone in Patients With Metastatic Hormone-sensitive Prostate Cancer (mHSPC)", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Hormone-Sensitive Prostate Cancer (mHSPC)" ], "interventions": [ { "name": "Tulmimetostat", "type": "DRUG" }, { "name": "Darolutamide", "type": "DRUG" }, { "name": "Abiraterone", "type": "DRUG" }, { "name": "Prednisone/Prednisolone", "type": "DRUG" }, { "name": "Androgen Deprivation Therapy (ADT)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Novartis Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "MALE", "summary": "18 Years and older · Male only" }, "enrollment_count": 181, "start_date": "2026-01-13", "completion_date": "2032-08-02", "has_results": false, "last_update_posted_date": "2026-09-29", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 8, "location_summary": "Birmingham, Alabama • Iowa City, Iowa • Westwood, Kansas + 5 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Iowa City", "state": "Iowa" }, { "city": "Westwood", "state": "Kansas" }, { "city": "Wichita", "state": "Kansas" }, { "city": "Durham", "state": "North Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT07190300" }, { "nct_id": "NCT03573544", "title": "This Study is to Evaluate Safe and Effective Treatment Dose of OBI-888 in Patients With Locally Advanced or Metastatic Solid Tumors.", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Metastatic Solid Tumors", "Locally Advanced Solid Tumors" ], "interventions": [ { "name": "OBI-888", "type": "DRUG" }, { "name": "Globo H IHC Assay", "type": "DEVICE" } ], "intervention_types": [ "DRUG", "DEVICE" ], "sponsor": "OBI Pharma, Inc", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 54, "start_date": "2018-05-07", "completion_date": "2022-04-07", "has_results": true, "last_update_posted_date": "2024-02-22", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 6, "location_summary": "La Jolla, California • Los Angeles, California • Newport Beach, California + 3 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Newport Beach", "state": "California" }, { "city": "New Brunswick", "state": "New Jersey" }, { "city": "Germantown", "state": "Tennessee" } ], "official_url": "https://clinicaltrials.gov/study/NCT03573544" }, { "nct_id": "NCT00392834", "title": "Rituximab and Combination Chemotherapy in Treating Patients With Newly Diagnosed, HIV-Associated Burkitt's Lymphoma", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Lymphoma" ], "interventions": [ { "name": "filgrastim", "type": "BIOLOGICAL" }, { "name": "pegfilgrastim", "type": "BIOLOGICAL" }, { "name": "rituximab", "type": "BIOLOGICAL" }, { "name": "cyclophosphamide", "type": "DRUG" }, { "name": "cytarabine", "type": "DRUG" }, { "name": "doxorubicin hydrochloride", "type": "DRUG" }, { "name": "etoposide", "type": "DRUG" }, { "name": "ifosfamide", "type": "DRUG" }, { "name": "leucovorin calcium", "type": "DRUG" }, { "name": "liposomal cytarabine", "type": "DRUG" }, { "name": "methotrexate", "type": "DRUG" }, { "name": "therapeutic hydrocortisone", "type": "DRUG" }, { "name": "vincristine sulfate", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "AIDS Malignancy Consortium", "sponsor_class": "NETWORK", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 34, "start_date": "2006-09", "completion_date": "2013-07", "has_results": true, "last_update_posted_date": "2018-06-06", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 13, "location_summary": "La Jolla, California • Los Angeles, California • San Francisco, California + 9 more", "locations": [ { "city": "La Jolla", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "San Francisco", "state": "California" }, { "city": "Baltimore", "state": "Maryland" } ], "official_url": "https://clinicaltrials.gov/study/NCT00392834" }, { "nct_id": "NCT05702853", "title": "Metabolically Fit CD19 CAR T-cell Therapy With CD34 Selection in Patients With CD19+ Relapsed/Refractory NHL, CLL/SLL", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "B-cell Non Hodgkin Lymphoma", "Chronic Lymphocytic Leukemia" ], "interventions": [ { "name": "Cyclophosphamide injection", "type": "DRUG" }, { "name": "Fludarabine Injection", "type": "DRUG" }, { "name": "CD19-CD34t metabolically programmed CAR transduced T-cells", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "Medical University of South Carolina", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 27, "start_date": "2023-11-06", "completion_date": "2026-12-30", "has_results": false, "last_update_posted_date": "2026-03-27", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 1, "location_summary": "Charleston, South Carolina", "locations": [ { "city": "Charleston", "state": "South Carolina" } ], "official_url": "https://clinicaltrials.gov/study/NCT05702853" }, { "nct_id": "NCT00944905", "title": "Study of MDX-1203 in Subjects With Advanced/Recurrent Clear Cell Renal Cell Carcinoma (ccRCC) or Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma (B-NHL)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Renal Cell Carcinoma", "Non-hodgkin's Lymphoma" ], "interventions": [ { "name": "MDX-1203", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 46, "start_date": "2009-07", "completion_date": "2012-11", "has_results": false, "last_update_posted_date": "2013-05-22", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 5, "location_summary": "New Haven, Connecticut • Atlanta, Georgia • Chicago, Illinois + 2 more", "locations": [ { "city": "New Haven", "state": "Connecticut" }, { "city": "Atlanta", "state": "Georgia" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Baltimore", "state": "Maryland" }, { "city": "Ann Arbor", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT00944905" }, { "nct_id": "NCT04301310", "title": "Study to Evaluate the Effect of Rifampin on the Drug Levels in Blood and Safety of BMS-986235 in Healthy Participants", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "BMS-986235 (Treatment A)", "type": "DRUG" }, { "name": "Rifampin (Treatment B)", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 0, "start_date": "2020-03-09", "completion_date": "2020-03-16", "has_results": false, "last_update_posted_date": "2022-03-31", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 1, "location_summary": "Salt Lake City, Utah", "locations": [ { "city": "Salt Lake City", "state": "Utah" } ], "official_url": "https://clinicaltrials.gov/study/NCT04301310" }, { "nct_id": "NCT06144697", "title": "A Study to Evaluate the Safety, Tolerability, Drug Levels, Food, Formulation, and pH Effects on Relative Absorption of BMS-986465 and Its Active Derivative BMS-986464 in Healthy Participants", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Participants" ], "interventions": [ { "name": "BMS-986465", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" }, { "name": "Pegasys", "type": "DRUG" }, { "name": "Famotidine", "type": "DRUG" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Bristol-Myers Squibb", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "18 Years to 55 Years" }, "enrollment_count": 267, "start_date": "2024-01-29", "completion_date": "2024-10-16", "has_results": false, "last_update_posted_date": "2025-02-06", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 2, "location_summary": "Anaheim, California • Austin, Texas", "locations": [ { "city": "Anaheim", "state": "California" }, { "city": "Austin", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT06144697" }, { "nct_id": "NCT07693751", "title": "A Study to Assess Safety and Efficacy of SOT109 in Patients With Advanced Unresectable or Metastatic Colorectal Cancer", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Colorectal Cancer (Locally Advanced or Metastatic)" ], "interventions": [ { "name": "SOT109", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "SOTIO Biotech a.s.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 100, "start_date": "2026-08-12", "completion_date": "2028-07-04", "has_results": false, "last_update_posted_date": "2026-09-21", "last_synced_at": "2026-10-28T13:39:31.223Z", "location_count": 2, "location_summary": "Houston, Texas • Faifax, Virginia", "locations": [ { "city": "Houston", "state": "Texas" }, { "city": "Faifax", "state": "Virginia" } ], "official_url": "https://clinicaltrials.gov/study/NCT07693751" } ] }